logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Vasomotor Menopausal Symptoms

    Medications for Vasomotor Menopausal Symptoms

    FiltersReset Filters
    9 results

    • bijuva

      (estradiol and progesterone)
      Mayne Pharma LLC
      Usage: The drug is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.

    • estradiol

      (ESTRADIOL)
      Solaris Pharma Corporation
      Usage: The drug is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy symptoms due to menopause. For vulvar and vaginal atrophy, topical products should be considered first.

    • estradiol and norethindrone acetate

      (Estradiol and Norethindrone Acetate)
      Ingenus Pharmaceuticals, LLC
      Usage: Estradiol and norethindrone acetate tablets are indicated for the treatment of moderate to severe vasomotor symptoms and vulvar/vaginal atrophy due to menopause, as well as for the prevention of postmenopausal osteoporosis in women at significant risk. Topical alternatives should be considered for certain conditions.

    • estrogel

      (estradiol)
      ASCEND Therapeutics US, LLC
      Usage: This drug is indicated for the treatment of moderate to severe vasomotor symptoms and moderate to severe vulvar and vaginal atrophy symptoms associated with menopause. For vulvar and vaginal atrophy, consider topical treatments first before prescribing this drug.

    • evamist

      (Estradiol)
      Padagis US LLC
      Usage: This drug is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.

    • femring

      (estradiol acetate)
      Millicent US, Inc.
      Usage: This drug is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause.

    • fyavolv

      (Norethindrone Acetate and Ethinyl Estradiol)
      Lupin Pharmaceuticals, Inc.
      Usage: This drug is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. However, estrogen therapy should only be considered for osteoporosis in women at significant risk, with non-estrogen options preferred.

    • norethindrone acetate and ethinyl estradiol

      (Norethindrone Acetate and Ethinyl Estradiol)
      Glenmark Pharmaceuticals Inc., USA
      Usage: The drug is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and for the prevention of postmenopausal osteoporosis, with emphasis on considering non-estrogen treatments first for osteoporosis prevention, reserving estrogen therapy for women at significant risk.

    • veozah

      (fezolinetant)
      Astellas Pharma US, Inc.
      Usage: VEOZAH® is indicated for treating moderate to severe vasomotor symptoms associated with menopause.